Preparation of highly potent and selective non-peptide antagonists of the arginine vasopressin V1A receptor by introduction of a 2-ethyl-1H-1-imidazolyl group

被引:9
|
作者
Shimada, Y
Akane, H
Taniguchi, N
Matsuhisa, A
Kawano, N
Kikuchi, K
Yatsu, T
Tahara, A
Tomura, Y
Kusayama, T
Wada, K
Tsukada, J
Tsunoda, T
Tanaka, A
机构
[1] Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Tsukuba, Ibaraki 3058585, Japan
[2] Yamanouchi Pharmaceut Co Ltd, Clin Dev Dept, Itabashi Ku, Tokyo 1748612, Japan
[3] Yamanouchi Pharmaceut Co Ltd, Chem Technol Lab, Ibaraki 3180001, Japan
[4] Yamanouchi Pharmaceut Co Ltd, Corp Commun Dept, Chuo Ku, Tokyo 1038411, Japan
关键词
arginine vasopressin; V-1A receptor selective antagonist; 2-ethyl-1H-1-imidazole;
D O I
10.1248/cpb.53.764
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
To find a new series of arginine vasopressin (AV]P) VIA receptor antagonists, the influence of the 2-phenyl group of 2-phenyl-4'-[(2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl)carbonyl]benzanilide (7) was investigated. Replacement of the 2-phenyl group by a 2-ethyl-1H-imidazol-1-yl group was effective in yielding a V-IA-selective compound. Moreover, this imidazolyl group was introduced in the same position in YM-35471 (6), and further studies of these compounds were performed. Consequently, we found that the (Z)-4'-({4,4-difluoro-5-[(N-cyclo-propylcarbamoyl)methylenel-2,3,4,5-tetrahydro-1H-1-benzazepin-1-yl}carbonyl)-2-(2-ethyl-1H-1-imidazol-1- yl)benzanilide (9f) exhibited highly potent affinity and selectivity, and was the most potent antagonist for the V,A receptor among our compounds. The synthesis and pharmacological evaluation of these compounds are described in this paper.
引用
收藏
页码:764 / 769
页数:6
相关论文
共 50 条
  • [41] DEAMINO1-PHENYLALANINE2-ARGININE8-VASOPRESSIN - A PEPTIDE WITH HIGHLY SELECTIVE ANTIDIURETIC ACTIVITY
    STURMER, E
    HUGUENIN, RL
    BOISSONNAS, RA
    BERDE, B
    EXPERIENTIA, 1965, 21 (10): : 583 - +
  • [42] Theoretical studies, synthesis, and biological activity of 1-[(4-methylphenyl)sulfonyl]-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine-4-carbonitrile (C9) as a non-peptide antagonist of the arginine vasopressin V1a and V2 receptors
    M. Citlalli Contreras-Romo
    José Correa-Basurto
    Itzia Padilla-Martínez
    Marlet Martínez-Archundia
    Federico Martínez-Ramos
    Magdalena J. Ślusarz
    Gilberto López-Pérez
    Andrés Quintanar-Stephano
    Medicinal Chemistry Research, 2014, 23 : 1581 - 1590
  • [43] Vascular Effects of RWJ-676070, a Selective Combined V1a/V2 Vasopressin Receptor Antagonist
    Coltamai, L.
    Bucher, M.
    Maillard, M. P.
    Shukla, U.
    Bohidar, N.
    Haskell, L.
    Bertelsen, K.
    Fedgchin, M.
    Vogt, B.
    Burnier, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009, 85 (02) : 145 - 148
  • [44] Recent advances in the discovery and development of vasopressin antagonists: Peptide and nonpeptide V-1a and V-2 receptor antagonists
    Albright, JD
    Chan, PS
    CURRENT PHARMACEUTICAL DESIGN, 1997, 3 (06) : 615 - 632
  • [45] Theoretical studies, synthesis, and biological activity of 1-[(4-methylphenyl)sulfonyl]-5-oxo-2,3,4,5-tetrahydro-1H-1-benzazepine-4-carbonitrile (C9) as a non-peptide antagonist of the arginine vasopressin V1a and V2 receptors
    Citlalli Contreras-Romo, M.
    Correa-Basurto, Jose
    Padilla-Martinez, Itzia
    Martinez-Archundia, Marlet
    Martinez-Ramos, Federico
    Slusarz, Magdalena J.
    Lopez-Perez, Gilberto
    Quintanar-Stephano, Andres
    MEDICINAL CHEMISTRY RESEARCH, 2014, 23 (03) : 1581 - 1590
  • [46] Design of potent and selective agonists for the human vasopressin V1b receptor based on modifications of [deamino-cys1]arginine vasopressin at position 4
    Cheng, LL
    Stoev, S
    Manning, M
    Derick, S
    Pena, A
    Ben Mimoun, M
    Guillon, G
    JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (09) : 2375 - 2388
  • [47] 1,4,5,6-tetrahydroimidazo[4,5-dl[1]benzazepine derivatives 2: Oral active non-peptide antagonists of arginine vasopressin receptors.
    Koshio, H
    Kakefuda, A
    Sato, I
    Wakayama, R
    Sanagi, M
    Tsukada, J
    Yatsu, T
    Sakamoto, S
    Tsukamoto, S
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2004, 228 : U913 - U913
  • [48] The selective V1a receptor agonist FE 202158 does not cause von Willebrand factor release in sheep unlike arginine vasopressin
    S Rehberg
    P Enkhbaatar
    R Laporte
    J Rehberg
    E La
    K Wisniewski
    LD Traber
    CD Schteingart
    PJM Riviere
    DL Traber
    Critical Care, 13 (Suppl 4):
  • [49] A single residue (Arg46) located within the N-terminus of the V1a vasopressin receptor is critical for binding vasopressin but not peptide or nonpeptide antagonists
    Hawtin, SR
    Wesley, VJ
    Parslow, RA
    Simms, J
    Miles, A
    McEwan, K
    Wheatley, M
    MOLECULAR ENDOCRINOLOGY, 2002, 16 (03) : 600 - 609
  • [50] Effect of novel selective non-peptide kinin B1 receptor antagonists on mouse pleurisy induced by carrageenan
    Costa, Robson
    Fernandes, Elizabeth S.
    Menezes-De-Lima, Octavio, Jr.
    Campos, Maria M.
    Calixto, Jodo B.
    PEPTIDES, 2006, 27 (11) : 2967 - 2975